Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Latest News about Tiziana Life Sciences Recent news which mentions Tiziana Life Sciences Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab November 30, 2023 Tickers TLSA Tags Partner Content Tiziana Life Sciences Biotech From Benzinga Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June October 12, 2023 Tickers TLSA Tags Penny Stocks Benzinga Market News From Benzinga Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update October 04, 2023 Tickers RHHBY SNY TLSA Tags Tiziana Life Sciences Biotech SNY From Benzinga Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients September 27, 2023 Tickers TLSA Tags General Biotech Tiziana Life Sciences From Benzinga Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light September 12, 2023 Tickers TLSA Tags TLSA Market News Penny Stocks From Benzinga Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision August 16, 2023 Tickers TLSA Tags Market News TLSA Penny Stocks From Benzinga As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab? August 08, 2023 Tickers BAYRY SNY TLSA Tags General Partner Content SNY From Benzinga Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon August 03, 2023 Tickers SNY TLSA Tags General Partner Content Biotech From Benzinga Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer? July 26, 2023 Tags General Partner Content Biotech From Benzinga Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment July 17, 2023 Tickers BAYRY SNY TSLA Tags General News SNY From Benzinga Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA) July 10, 2023 Tickers SNY TLSA Tags Penny Stocks Benzinga TLSA From Benzinga Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company? June 15, 2023 Tickers PRVB SNY TLSA Tags General Partner Content PRVB From Benzinga Tiziana's Foralumab Shown To Reduce Microglial Activation In MS Patients; Phase 2a Trial To Begin In Q3 2023 June 06, 2023 Tickers TLSA Tags General Tiziana Life Sciences Biotech From Benzinga Tiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a Trial April 21, 2023 Tickers TLSA Tags TLSA Market News Benzinga From Benzinga Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis April 19, 2023 Tickers EWTX IPHA PRVB SGEN Tags Penny Stocks TBPH Benzinga From Benzinga Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise April 12, 2023 Tickers PRVB SNY TLSA Tags General Partner Content PRVB From Benzinga Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS) March 29, 2023 Tickers TLSA Tags General Tiziana Life Sciences Biotech From Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
